Patents by Inventor Isabel Najera

Isabel Najera has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPY OF AN HBV CAPSID ASSEMBLY INHIBITOR AND AN INTERFERON
    Publication number: 20200276198
    Abstract: The present invention is directed to compositions and methods for treating hepatitis B virus infection. In particular, the present invention is directed to a combination therapy comprising administration of an HBV capsid assembly inhibitor and an interferon for use in the treatment of hepatitis B virus infections.
    Type: Application
    Filed: March 20, 2020
    Publication date: September 3, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Lu Gao, Isabel Najera, Hong Shen, Fang Shen, Liping Shi, Steffen Wildum, Guang Yang
  • Combination therapy of an HBV capsid assembly inhibitor and an interferon
    Patent number: 10596173
    Abstract: The present invention is directed to compositions and methods for treating hepatitis B virus infection. In particular, the present invention is directed to a combination therapy comprising administration of an HBV capsid assembly inhibitor and an interferon for use in the treatment of hepatitis B virus infections.
    Type: Grant
    Filed: May 3, 2018
    Date of Patent: March 24, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Lu Gao, Isabel Najera, Hong Shen, Fang Shen, Liping Shi, Steffen Wildum, Guang Yang
  • Pyridazinone-based broad spectrum anti-influenza inhibitors
    Patent number: 10597380
    Abstract: The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, as well as processes for their manufacture, pharmaceutical compositions comprising them, and their use as medicaments.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: March 24, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: John G. Cumming, Xianfeng Lin, Haixia Liu, Isabel Najera, Zongxing Qiu, Virginie Sandrin, Guozhi Tang, Guolong Wu
  • COMBINATION THERAPY OF AN HBV CAPSID ASSEMBLY INHIBITOR AND A NUCLEOS(T)IDE ANALOGUE
    Publication number: 20190275052
    Abstract: The present invention is directed to compositions and methods for treating hepatitis B virus infection. In particular, the present invention is directed to a combination therapy comprising administration of an HBV capsid assembly inhibitor and a nucleoside or nucleotide analogue for use in the treatment or prophylaxis of chronic hepatitis B patient.
    Type: Application
    Filed: February 22, 2019
    Publication date: September 12, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Isabel Najera, Steffen Wildum
  • PYRIDAZINONE-BASED BROAD SPECTRUM ANTI-INFLUENZA INHIBITORS
    Publication number: 20190127349
    Abstract: The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, as well as processes for their manufacture, pharmaceutical compositions comprising them, and their use as medicaments.
    Type: Application
    Filed: December 19, 2018
    Publication date: May 2, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: John G. CUMMING, Xianfeng LIN, Haixia LIU, Isabel NAJERA, Zongxing QIU, Virginie SANDRIN, Guozhi TANG, Guolong WU
  • COMBINATION THERAPY OF AN HBV CAPSID ASSEMBLY INHIBITOR AND AN INTERFERON
    Publication number: 20180250301
    Abstract: The present invention is directed to compositions and methods for treating hepatitis B virus infection. In particular, the present invention is directed to a combination therapy comprising administration of an HBV capsid assembly inhibitor and an interferon for use in the treatment of hepatitis B virus infections.
    Type: Application
    Filed: May 3, 2018
    Publication date: September 6, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Lu Gao, Isabel Najera, Hong Shen, Fang Shen, Liping Shi, Steffen Wildum, Guang Yang
  • 4?-substituted nucleoside derivatives as inhibitors of HCV RNA replication
    Patent number: 8648054
    Abstract: The present invention relates to the use of nucleoside derivatives of formula Ia wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof and to pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: April 12, 2013
    Date of Patent: February 11, 2014
    Assignee: Roche Palo Alto LLC
    Inventors: Rene Robert Devos, Christopher John Hobbs, Wen-Rong Jiang, Joseph Armstrong Martin, John Herbert Merrett, Isabel Najera, Nobuo Shimma, Takuo Tsukuda
  • 4'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION
    Publication number: 20130237491
    Abstract: The present invention relates to the use of nucleoside derivatives of formula Ia wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof and to pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: April 12, 2013
    Publication date: September 12, 2013
    Applicant: Roche Palo Alto LLC
    Inventors: Rene Robert Devos, Christopher John Hobbs, Wen-Rong Jiang, Joseph Armstrong Martin, John Herbert Merrett, Isabel Najera, Nobuo Shimma, Takuo Tsukuda
  • 4'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION
    Publication number: 20120034184
    Abstract: The present invention relates to the use of nucleoside derivatives of formula I wherein B signifies a 9-purinyl residue B1 of formula or a 1-pyrimidyl residue B2 of formula wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof; for the treatment of diseases mediated by the Hepatitis C Virus (HCV), for the preparation of a medicament for such treatment and to pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: October 17, 2011
    Publication date: February 9, 2012
    Inventors: Rene Robert Devos, Christopher John Hobbs, Wen Rong Jiang, Joseph Armstrong Martin, John Herbert Merrett, Isabel Najera, Nobuo Shimma, Takuo Tsukuda
  • 4?-substituted nucleoside derivatives as inhibitors of HCV RNA replication
    Patent number: 8071567
    Abstract: The present invention relates to the use of nucleoside derivatives of formula Ia wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof and to pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: September 16, 2009
    Date of Patent: December 6, 2011
    Assignee: Roche Palo Alto LLC
    Inventors: Rene Robert Devos, Christopher John Hobbs, Wen Rong Jiang, Joseph Armstrong Martin, John Herbert Merrett, Isabel Najera, Nobuo Shimma, Takuo Tsukuda
  • HCV NS5A Replicon Shuttle Vectors
    Publication number: 20110245328
    Abstract: The present invention provides for novel HCV NS5A replicon shuttle vectors useful for cloning in HCV polynucleotide sequences from samples of HCV-infected patients and testing the resulting replicons for drug susceptibility.
    Type: Application
    Filed: March 3, 2011
    Publication date: October 6, 2011
    Inventors: Hyunsoon Kang, Sophie Le Pogam, Isabel Najera
  • 4?-substituted nucleoside derivatives as inhibitors of HCV RNA replication
    Patent number: 7915232
    Abstract: The present invention relates to the use of nucleoside derivatives of formula Ia wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof which inhibit HCV polymerase and are useful for treating a patient suffering from a HCV infection and to pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: September 14, 2009
    Date of Patent: March 29, 2011
    Assignee: Roche Palo Alto LLC
    Inventors: Joseph Armstrong Martin, John Herbert Merrett, Isabel Najera, Rene Robert Devos, Christopher John Hobbs, Wen Rong Jiang, Nobuo Shimma, Takuo Tsukuda
  • HCV NS3/4A REPLICON SHUTTLE VECTORS
    Publication number: 20110053160
    Abstract: The present invention provides for novel HCV NS3/4A replicon shuttle vectors useful for cloning in HCV polynucleotide sequences from samples of HCV-infected patients and testing the resulting replicons for drug susceptibility.
    Type: Application
    Filed: August 31, 2010
    Publication date: March 3, 2011
    Inventors: SAMIR ALI, MILLONI B. CHHABRA, MARIA JOLANTA ILNICKA, WEN-RONG JIANG, ISABEL NAJERA
  • PRODUCTION OF INFECTIOUS HEPATITIS C VIRUS PARTICLES IN CELL CULTURE
    Publication number: 20100068698
    Abstract: The present invention provides for novel methods of producing high levels of infectious HCV genotype 1 virus particles in cell culture systems. The availability of HCV genotype 1 virus (principally associated with liver disease in most regions of the world) that can undergo the complete viral cycle in cultured cells is beneficial for the discovery and development of novel therapies for the treatment of HCV.
    Type: Application
    Filed: September 11, 2009
    Publication date: March 18, 2010
    Inventors: Matthew F. McCown, Isabel Najera
  • 4'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION
    Publication number: 20100003213
    Abstract: The present invention relates to the use of nucleoside derivatives of formula Ia wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof and to pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: September 16, 2009
    Publication date: January 7, 2010
    Inventors: Rene Robert Devos, Christopher John Hobbs, Wen Rong Jiang, Joseph Armstrong Martin, John Herbert Merrett, Isabel Najera, Nobuo Shimma, Takuo Tsukuda
  • 4'-Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
    Publication number: 20100004192
    Abstract: The present invention relates to the use of nucleoside derivatives of formula Ia wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof and to pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: September 14, 2009
    Publication date: January 7, 2010
    Inventors: Joseph Armstrong Martin, John Herbert Merrett, Isabel Najera, Rene Robert Devos, Christopher John Hobbs, Wen Rong Jiang, Nobuo Shimma, Takuo Tsukuda
  • 4?-Substituted nucleoside derivatives as inhibitors of HCV RNA replication
    Patent number: 7608601
    Abstract: The present invention relates to the use of nucleoside derivatives of formula I wherein B signifies a 9-purinyl residue B1 of formula or a 1-pyrimidyl residue B2 of formula wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof; for the treatment of diseases mediated by the Hepatitis C Virus (HCV), for the preparation of a medicament for such treatment and to pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: July 15, 2004
    Date of Patent: October 27, 2009
    Assignee: Roche Palo Alto LLC
    Inventors: Rene Robert Devos, Christopher John Hobbs, Wen Rong Jiang, Joseph Armstrong Martin, John Herbert Merrett, Isabel Najera, Nobuo Shimma, Takuo Tsukuda
  • HCV NS3 replicon shuttle vectors
    Publication number: 20090004664
    Abstract: The present invention provides for novel HCV NS3 replicon shuttle vectors useful for cloning in HCV polynucleotide sequences from samples of HCV-infected patients and testing the resulting replicons for drug susceptibility.
    Type: Application
    Filed: June 5, 2008
    Publication date: January 1, 2009
    Inventors: Pong Kian Chua, Isabel Najera
  • HCV replicon shuttle vectors
    Publication number: 20080026952
    Abstract: The present invention provides for novel HCV replicon shuttle vectors useful for cloning in HCV polynucleotide sequences from samples of HCV-infected patients and testing the resulting replicons for drug susceptibility.
    Type: Application
    Filed: December 18, 2006
    Publication date: January 31, 2008
    Inventors: Paul Dietrich, Alan Kosaka, Sophie Pogam, Isabel Najera
  • 4'-Substituted nucleoside derivatives as inhibitors of HCV RNA replication
    Publication number: 20040266722
    Abstract: The present invention relates to the use of nucleoside derivatives of formula I 1
    Type: Application
    Filed: July 15, 2004
    Publication date: December 30, 2004
    Inventors: Rene Robert Devos, Christopher John Hobbs, Wen Rong Jiang, Joseph Armstrong Martin, John Herbert Merrett, Isabel Najera, Nobuo Shimma, Takuo Tsukuda